Ipratropium Nebules

Ipratropium Nebules

Form: Nebulizer Solution

Strength: 250 mcg/2 mL, 500 mcg/2 mL

Reference Brands: Atrovent(US & EU)

Category: Critical Care

Ipratropium Nebules are inhalation solutions used via nebulizer to treat chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. These anticholinergic bronchodilators are commonly available in unit-dose formats like 250 mcg/2 mL and 500 mcg/2 mL, as well as in multi-dose vials (0.025–0.05%). In the US, Ipratropium is marketed as Atrovent by Boehringer Ingelheim and via generics by Teva and Nephron. In the EU, Atrovent and its equivalents are produced by Sandoz, Teva, and Stada. Pharma B2B platforms ensure consistent supply of Ipratropium Nebules for hospitals, clinics, and respiratory therapy centers treating obstructive airway disorders.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.